The Phase 1/2 open-label, dose-escalation and expansion study ( NCT06667960 ) to assess the safety, pharmacokinetics, and preliminary efficacy of JK06 is ongoing, and the cohort expansion phase, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback